Banner

Neutropenia Biologic Drug Treatment Global Market Report 2023 – By Drug Type (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim), By Treatment Type (Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (g csf), Antifungal Drugs, Other Treatment Types), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Market Size, Trends, And Market Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | SKU CODE : h1188 | Delivery Time: 2-3 business days | Format :


Neutropenia biologic drug treatment refers to drugs that are used to reduce fevers or potential infections as well as activate the bone marrow and boost neutrophil production. A lack of neutrophils, a particular type of white blood cell, causes neutropenia.

The main types of drugs in neutropenia biologic drug treatment are filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim is a recombinant form of granulocyte colony-stimulating protein that is given as an injection to boost neutrophil production after chemotherapy. The different types of treatments include antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, and others, and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies.

The neutropenia biologic drug treatment market research report is one of a series of new reports from The Business Research Company that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The global neutropenia biologic drug treatment market grew from $11.26 billion in 2022 to $12.29 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neutropenia biologic drug treatment market is expected to grow from $15.79 billion in 2027 at a CAGR of 6.5%.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the market for neutropenia biologic drugs. Due to a growing cancer incidence and an increase in the number of people opting for chemotherapy, there has been an increase in the number of people suffering from neutropenia. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the neutropenia biologic drug treatment market over the forthcoming years.

The introduction of biosimilars as a result of patent expiry is expected to hamper the growth of the neutropenia biologic drug treatment market. Biosimilar is a therapeutic agent that has high similarity with the original biological product in action but is available at a lower cost than the original product. Biosimilars are mostly priced at 70% of the price of branded drugs and are likely to replace expensive branded drugs. For instance, in May 2022, Biocon Biologics Limited, an India-based biopharmaceutical company specialising in the development of biological drugs, launched Abevmy® (bBevacizumab) in collaboration with Viatris Inc., a US-based healthcare and biopharmaceutical company pioneering in the development of medicines, advancing sustainable operations, and developing innovative solutions. Abevmy® (bBevacizumab) is being developed to treat various types of cancer, including solid tumors.

Companies in the neutropenia biologic drug treatment market are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disabling side effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells and is used for treating severe neutrophil-mediated disease.

In September 2020, Gilead Sciences, a US-based biopharmaceutical company, launched Immunomedics for $21 billion. Through this acquisition, Gilead will get TrodelvyTM ( acituzumabgovitecan-hziy), which will alter Gilead’s portfolio by adding a first-in-class commercial drug with considerable revenue potential and best-in-class potential. Immunomedics is a biotechnology company based in the United States that provides biologic drug treatment for neutropenia.

Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp., Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.

North America was the largest region in the neutropenia biologic drug treatment market in 2022.

The regions covered in the global neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The global neutropenia biologic drug treatment market is segmented -

1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim

2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

    Table Of Contents

    1. Executive Summary

    2. Neutropenia Biologic Drug Treatment Market Characteristics

    3. Neutropenia Biologic Drug Treatment Market Trends And Strategies

    4. Neutropenia Biologic Drug Treatment Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Neutropenia Biologic Drug Treatment Market

    4.2 Ukraine-Russia War Impact On Neutropenia Biologic Drug Treatment Market

    4.3 Impact Of High Inflation On Neutropenia Biologic Drug Treatment Market

    5. Neutropenia Biologic Drug Treatment Market Size And Growth

    5.1. Global Neutropenia Biologic Drug Treatment Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Neutropenia Biologic Drug Treatment Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Neutropenia Biologic Drug Treatment Market Segmentation

    6.1. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Filgrastim

    Pegfilgrastim

    Lenograstim

    Lipegfilgrastim

    Sargramostim

    6.2. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Antibiotic Drugs

    Granulocyte-Colony-Stimulating Factor (G-CSF)

    Antifungal Drugs

    Others

    6.3. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Retail Pharmacies

    Hospital Pharmacies

    Online Pharmacies

    7. Neutropenia Biologic Drug Treatment Market Regional And Country Analysis

    7.1. Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Neutropenia Biologic Drug Treatment Market

    8.1. Asia-Pacific Neutropenia Biologic Drug Treatment Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Neutropenia Biologic Drug Treatment Market

    9.1. China Neutropenia Biologic Drug Treatment Market Overview

    9.2. China Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Neutropenia Biologic Drug Treatment Market

    10.1. India Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Neutropenia Biologic Drug Treatment Market

    11.1. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Neutropenia Biologic Drug Treatment Market

    12.1. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Neutropenia Biologic Drug Treatment Market

    13.1. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Neutropenia Biologic Drug Treatment Market

    14.1. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Neutropenia Biologic Drug Treatment Market

    15.1. Western Europe Neutropenia Biologic Drug Treatment Market Overview

    15.2. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Neutropenia Biologic Drug Treatment Market

    16.1. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Neutropenia Biologic Drug Treatment Market

    17.1. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Neutropenia Biologic Drug Treatment Market

    18.4. France Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Neutropenia Biologic Drug Treatment Market

    19.1. Eastern Europe Neutropenia Biologic Drug Treatment Market Overview

    19.2. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Neutropenia Biologic Drug Treatment Market

    20.1. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Neutropenia Biologic Drug Treatment Market

    21.1. North America Neutropenia Biologic Drug Treatment Market Overview

    21.2. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Neutropenia Biologic Drug Treatment Market

    22.1. USA Neutropenia Biologic Drug Treatment Market Overview

    22.2. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Neutropenia Biologic Drug Treatment Market

    23.1. South America Neutropenia Biologic Drug Treatment Market Overview

    23.2. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Neutropenia Biologic Drug Treatment Market

    24.1. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Neutropenia Biologic Drug Treatment Market

    25.1. Middle East Neutropenia Biologic Drug Treatment Market Overview

    25.2. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Neutropenia Biologic Drug Treatment Market

    26.1. Africa Neutropenia Biologic Drug Treatment Market Overview

    26.2. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Neutropenia Biologic Drug Treatment Market Competitive Landscape And Company Profiles

    27.1. Neutropenia Biologic Drug Treatment Market Competitive Landscape

    27.2. Neutropenia Biologic Drug Treatment Market Company Profiles

    27.2.1. Teva Pharmaceutical

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Amgen

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Sanofi

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Mylan

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Kyowa Kirin

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Neutropenia Biologic Drug Treatment Pipeline Analysis

    29. Key Mergers And Acquisitions In The Neutropenia Biologic Drug Treatment Market

    30. Neutropenia Biologic Drug Treatment Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Teva Pharmaceutical Financial Performance
  • Table 47: Amgen Financial Performance
  • Table 48: Sanofi Financial Performance
  • Table 49: Mylan Financial Performance
  • Table 50: Kyowa Kirin Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Teva Pharmaceutical Financial Performance
  • Figure 47: Amgen Financial Performance
  • Figure 48: Sanofi Financial Performance
  • Figure 49: Mylan Financial Performance
  • Figure 50: Kyowa Kirin Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report